Mirtazapine Mylan (Mirtazapine)

Mirtazapine works by blocking central α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonizing 5‑HT2 and 5‑HT3 serotonin receptors. This dual action enhances noradrenergic and serotonergic neurotransmission, correcting the chemical imbalances associated with depression.

The appropriate dose of Mirtazapine Mylan is determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Dosage adjustments are made according to clinical guidelines and patient-specific factors.

Safety data for mirtazapine in pregnancy and lactation are limited. Prescribers should weigh the potential benefits against possible risks and consider alternative treatments when possible. Breastfeeding mothers should consult their healthcare provider before using the medication.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined α2‑adrenergic blockade and serotonin receptor antagonism. This profile often results in pronounced sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Store Mirtazapine Mylan tablets at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Mirtazapine Mylan is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis or severe neutropenia, hepatic dysfunction, severe hypersensitivity reactions, emergence of suicidal thoughts especially early in therapy, and serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored closely for these events.

Mirtazapine is contraindicated in patients who have taken a monoamine oxidase inhibitor within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder, as it may trigger manic episodes.